Home › Research › Treatments
Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations
So Yeon Jeon, Min Soo Byun, Hye Ji Choi, Yoon Hee Kim, Chung Hee Gwag, Yoonseok Oh, Jee Eun Park, Dahyun Yi et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025-11
Topic: Drug trials: efficacy and safety
Among 1005 amyloid-positive participants, 24.6% were eligible for lecanemab and 28.0% for donanemab (9.1% and 10.3% of the initial sample). Applying MMSE z-scores increased eligibility to 38.4% and 33.7%, respectively. Over a third of participants were excluded due to MRI findings, mainly vascular lesions associated with increased amyloid-related imaging-abnormality risks. Incorporating demographically adjusted MMSE z-score threshold improves real-world eligibility and promotes equitable access to anti-amyloid therapies. HIGHLIGHTS: About a fourth of A+ patients in Korea met AUR criteria for anti-amyloid therapy. Donanemab eligibility slightly exceeded lecanemab despite narrower age criteria. MMSE z-score adjustment increased eligibility in older, less-educated individuals. Over 30% of eligible patients were excluded due to ARIA-related MRI findings. Culturally adapted cognitive thresholds are essential for equitable treatment access.
Key findings
- Among 1005 amyloid-positive participants, 24.6% were eligible for lecanemab and 28.0% for donanemab (9.1% and 10.3% of the initial sample).
- Applying MMSE z-scores increased eligibility to 38.4% and 33.7%, respectively.
- Over a third of participants were excluded due to MRI findings, mainly vascular lesions associated with increased amyloid-related imaging-abnormality risks.
- Incorporating demographically adjusted MMSE z-score threshold improves real-world eligibility and promotes equitable access to anti-amyloid therapies.
- HIGHLIGHTS: About a fourth of A+ patients in Korea met AUR criteria for anti-amyloid therapy.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants2,726
- Effect size24.6%; 28.0%; 9.1%
- Evidence strengthLow
How this study scored 61/100
Published in a leading specialty journal. Scored zero for study design and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 34 of the 56 points we could judge it on, which is 61 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 2,726 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41225766) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 34 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 34 of the 56 points we could judge it on is 61 out of 100. |
| Total | 61 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Jeon, S. Y., Byun, M. S., Choi, H. J., Kim, Y. H., Gwag, C. H., Oh, Y., et al. (2025). Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.70875
Vancouver
Jeon SY, Byun MS, Choi HJ, Kim YH, Gwag CH, Oh Y, et al. Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. doi:10.1002/alz.70875. PMID: 41225766.
BibTeX
@article{jeon2025-41225766,
author = {Jeon, So Yeon and Byun, Min Soo and Choi, Hye Ji and Kim, Yoon Hee and Gwag, Chung Hee and Oh, Yoonseok and Park, Jee Eun and Yi, Dahyun and others},
title = {{Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2025},
doi = {10.1002/alz.70875},
pmid = {41225766},
url = {https://doi.org/10.1002/alz.70875}
}
Related studies in Treatments
Also tagged “aducanumab”
332 studies in the library carry the topic tag “aducanumab”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.